148416-38-0

Basic information

• Product Name: 2,3,4-Trifluoro-6-nitroaniline
• Synonyms: 6-NITRO-2,3,4-TRIFLUOROANILINE;2-NITRO-4,5,6-TRIFLUOROANILINE;2,3,4-TRIFLUORO-6-NITROANILINE;BUTTPARK 24\01-62;6-Nitro-2,3,4-trifluoroaniline 97%;6-Nitro-2,3,4-trifluoroaniline97%;2,3,4-TRIFLUORO-6-NITROANILINE 99%;2,3,4-Trifluoro-6-ni
• CAS NO: 148416-38-0
• Molecular Formula: C₆H₃F₃N₂O₂
• Molecular Weight: 192.1
• Product Categories: Amines;C2 to C6;Nitrogen Compounds
• Mol File: 148416-38-0.mol

Chemical Properties

• Melting Point: 59-61 °C(lit.)
• Boiling Point: 287.6 °C at 760 mmHg
• Flash Point: 127.7 °C
• Appearance: White/Powder
• Density: 1.653 g/cm³
• Vapor Pressure: 0.27mmHg at 25°C
• Refractive Index: 1.451
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: -2.75±0.25(Predicted)
• CAS DataBase Reference: 2,3,4-Trifluoro-6-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4-Trifluoro-6-nitroaniline(148416-38-0)
• EPA Substance Registry System: 2,3,4-Trifluoro-6-nitroaniline(148416-38-0)

Safety Data

• Hazard Codes: Xi,T,Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36-36/37/39
• WGK Germany: 3
• HazardClass: TOXIC
• Hazardous Substances Data: 148416-38-0(Hazardous Substances Data)

Usage

Chemical Properties

White to yellow solid

InChI:InChI=1/C9H7F3O3/c1-14-8(13)6-4-2-3-5-7(6)15-9(10,11)12/h2-5H,1H3

Upstream product

• 365-29-7 N-(2,3,4-trifluorophenyl)acetamide 
• 290313-50-7 6-nitro-2,3,4-trifluoroacetanilide 
• 5580-79-0 2,3,4,5-tetrafluoro-1-nitrobenzene 
• 3862-73-5 2,3,4-trifluoroaniline 

Downstream Products

• 168966-54-9 3,4,5-Trifluoro-1,2-phenylenediamine 
• 587847-30-1 4,5,6-trifluoro-2-nitrophenylazide 
• 66684-58-0 3,4,5-trifluoronitrobenzene 
• 934765-48-7 4-[(3-amino-2,6-difluoro-4-nitrophenyl)oxy]benzaldehyde 
• 1477492-17-3 2,6-difluoro-N₁-(4-fluorobenzyl)-4-nitrobenzene-1,3-diamine 
• 1477492-04-8 ethyl (2-amino-3,5-difluoro-4-((4-fluorobenzyl)amino)phenyl)carbamate 
• 1196131-58-4 5,6,7-triifluoro-2-phenyl-1H-benzimidazole 

Relevant articles and documents

Fluorinated 2-Amino-4-(Benzylamino)Phenylcarbamate Derivatives

The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.

A PROCESS FOR THE PREPARATION OF 3,4,5-TRIFLUORONITROBENZENE

The present invention relates to a process for the preparation of 3,4,5-trifluoronitrobenzene of the formula (1). The process involved straightforward transformations and eventually culminated in consistent preparation of the title compound in good quantities.

Synthesis of novel fluorobenzofuroxans by oxidation of anilines and thermal cyclization of arylazides

The synthesis of several fluorobenzofuroxans by oxidation of fluoroanilines and thermal cyclization of fluoroarylazides is presented. The fluorobenzofuroxans prepared in this study presented tautomerism as evidenced by their NMR data. Benzofuroxans in general have biological activity and are synthetic intermediates for the preparation of several compounds with important pharmaceutical applications.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.